Patents by Inventor Fangyong Du

Fangyong Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220090053
    Abstract: A recombinant polynucleotide suitable for use in a display vector is provided. The recombinant polynucleotide includes from 5? to 3?: a first nucleic acid sequence (or insert) encoding an amino acid sequence to be displayed on a surface; a first pre-selected restriction site; a second nucleic acid sequence encoding a surface peptide capable of being displayed on the surface; and a second pre-selected restriction site. Corresponding display vectors that can be converted into expression vectors in a high-throughput fashion, as well as methods of use thereof, are also provided.
    Type: Application
    Filed: December 1, 2021
    Publication date: March 24, 2022
    Inventors: Fangyong DU, Peter Peizhi LUO
  • Publication number: 20220089757
    Abstract: Provided herein are antibodies that bind to an intracellular/transmembrane portion of human CD137L, as well as methods relating to the use of these antibodies for detecting CD137L expression in a sample and the detection of CD137L expression as a biomaker for cancer treatment.
    Type: Application
    Filed: June 4, 2020
    Publication date: March 24, 2022
    Applicant: ADAGENE PTE. LTD.
    Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU
  • Patent number: 11242395
    Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
  • Publication number: 20210207126
    Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.
    Type: Application
    Filed: February 2, 2019
    Publication date: July 8, 2021
    Inventors: Peter Peizhi LUO, Fangyong DU
  • Publication number: 20210206855
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Application
    Filed: February 2, 2019
    Publication date: July 8, 2021
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
  • Publication number: 20210122824
    Abstract: The present disclosure provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligand1 (PD-L1) protein, and methods of use. In various embodiments of the disclosure, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present disclosure provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the disclosure are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Inventors: Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li
  • Publication number: 20200377608
    Abstract: Provided herein are methods relating to the use of CD137 Ligand (CD137L) expression; methods relating to the use of CD137L expression as a biomarker; and methods for predicting, assessing, and/or aiding in assessment of responsiveness of a subject in need thereof to treatment with particular anti-cancer therapies (e.g., an anti-CD137 antibody, a checkpoint blockade immunotherapy).
    Type: Application
    Filed: November 30, 2018
    Publication date: December 3, 2020
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Guizhong LIU, Fangyong DU
  • Publication number: 20200369776
    Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 26, 2020
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Fangyong DU, Guizhong LIU, Yan LI, Jun CHEN, Xiaohong SHE, Peter CHEUNG
  • Publication number: 20200362019
    Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody light chain with specific hypervariable regions HVR-L1, HVR-L2, and HVR-L3. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody light chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.
    Type: Application
    Filed: August 21, 2017
    Publication date: November 19, 2020
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
  • Publication number: 20200248336
    Abstract: Provided herein are libraries containing polynucleotides, where one of the polynucleotides encodes an antibody heavy chain with specific hypervariable regions HVR-H1 and HVR-H2. Further provided herein are libraries containing polynucleotides encoding a plurality of unique antibodies, wherein each antibody comprises a heavy chain variable region and a light chain variable region. Also provided are antibodies, polypeptide libraries, vector libraries, cells, non-human animals, antibody heavy chains, methods of making an antibody library, kits, and methods of generating a bispecific antibody related thereto.
    Type: Application
    Filed: August 21, 2017
    Publication date: August 6, 2020
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Yan LI, Fangyong DU
  • Publication number: 20190241662
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Application
    Filed: February 1, 2019
    Publication date: August 8, 2019
    Applicant: ADAGENE INC.
    Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
  • Publication number: 20190241886
    Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.
    Type: Application
    Filed: February 1, 2019
    Publication date: August 8, 2019
    Applicant: ADAGENE INC.
    Inventors: Fangyong Du, Peter Peizhi Luo
  • Publication number: 20190062760
    Abstract: Methods and systems for autoinduction of gene expression, without the need to add exogenous inducers. A dual genetic element system, which includes a first, high copy number genetic element comprising a first gene of interest that is under the control of an inducible promoter, and a second, low copy number genetic element comprising a gene encoding a transcriptional factor which, upon expression, regulates transcription from the inducible promoter, wherein activation of transcription from the inducible promoter does not require addition of an exogenous inducer.
    Type: Application
    Filed: December 19, 2014
    Publication date: February 28, 2019
    Inventors: Fangyong Du, Peter Peizhi Luo
  • Publication number: 20190055314
    Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
  • Publication number: 20160145604
    Abstract: A recombinant polynucleotide suitable for use in a display vector is provided. The recombinant polynucleotide includes from 5? to 3?: a first nucleic acid sequence (or insert) encoding an amino acid sequence to be displayed on a surface; a first pre-selected restriction site; a second nucleic acid sequence encoding a surface peptide capable of being displayed on the surface; and a second pre-selected restriction site. Corresponding display vectors that can be converted into expression vectors in a high-throughput fashion, as well as methods of use thereof, are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 26, 2016
    Inventors: Fangyong Du, Peter Peizhi Luo
  • Publication number: 20040023311
    Abstract: The invention provides methods and compositions for modulating angiogenesis in a subject. The methods of modulating angiogenesis in a subject include administering to the subject a modulator of N-terminal cysteine oxygenase activity. The invention also provides a method of identifying such a modulator and a method of in vitro screening for modulators of N-terminal cysteine oxygenase activity. Additionally, the invention provides a method of treating an angiogenesis-related disorder.
    Type: Application
    Filed: March 21, 2003
    Publication date: February 5, 2004
    Inventors: Yong Tae Kwon, Ilia V. Davydov, Rong-gui Hu, Fangyong Du, Alexander Varshavsky